
CONNAUGHT

PENICILLIN-FREE POLIOMYELITIS VACCINE

POLIOMYELITIS VACCINE

Poliomyelitis Vaccine as prepared by the Connaught Medical Research Laboratories is now free of penicillin, as are also the following combined preparations:

DPT POLIO VACCINE

Diphtheria and Tetanus Toxoids
combined with
Pertussis and Poliomyelitis Vaccine

For the immunization of Infants and Pre-school children ONLY. NOT for school children, adolescents or adults.

DT POLIO VACCINE

Diphtheria and Tetanus Toxoids
combined with
Poliomyelitis Vaccine

For REINFORCING doses only in school children. NOT for older adolescents or for adults.

TETANUS-POLIO VACCINE

Tetanus Toxoid and
Poliomyelitis Vaccine
(Combined)

For the immunization of adults against both tetanus and poliomyelitis.



CONNAUGHT MEDICAL RESEARCH LABORATORIES
UNIVERSITY OF TORONTO
TORONTO 4, CANADA

*Established in 1914 for Public Service through
Medical Research and the development of
Products for Prevention or Treatment of Disease.*

THE CANADIAN MEDICAL ASSOCIATION
JOURNAL
LE JOURNAL DE
L'ASSOCIATION MÉDICALE CANADIENNE

Editorial Office—150 St. George St., Toronto 5

General Secretary's Office—150 St. George St., Toronto 5

SUBSCRIPTION RATES

The Journal is supplied to paid-up members of the Canadian Medical Association as a perquisite of membership. Medical libraries, hospitals, and individuals may subscribe to the Journal at \$12.00 a year, payable in advance. There is a special rate for medical students residing in Canada of \$2.50 a year. Subscriptions and all relative correspondence should be addressed to the Subscription Department, Canadian Medical Association Journal, 150 St. George Street, Toronto 5, Ontario.

INSTRUCTIONS TO CONTRIBUTORS

Manuscripts: Manuscripts of original articles, case reports, short communications, and special articles should be submitted to the Editor at the C.M.A.J. editorial office, 150 St. George St., Toronto, with a covering letter requesting consideration for publication in the *Journal*. Acceptance is subject to the understanding that they are submitted solely to this *Journal*, and will not be reprinted without the consent of both the Editor and the author. Articles should be typed on one side only of unruled paper, double-spaced and with wide margins. Carbon copies cannot be accepted. The author should always retain a carbon copy of material submitted. Every article should contain a summary of the contents.

The Editor reserves the right to make the usual editorial changes in manuscripts; these include such changes as are necessary to ensure correctness of grammar and spelling, clarification of obscurities or conformity to *Journal* style. In no case will major changes be made without prior consultation with the author. Authors will receive galley proofs of articles before publication, and are asked to confine alterations of such proofs to a minimum.

Reprints may be ordered on a form supplied with galley proofs.

References: Authors should limit references to published work to the minimum necessary for guidance to readers wishing to study the subject further. They should not quote articles they have never seen. Except in review articles, the maximum number of references should not be more than 25. References should be numbered in the text and should be set out in a numbered list at the end of the article, thus:

1. DOAKES, J.: *M. J. Kamchatka*, 1: 2, 1955, giving in order: (1) Author's name and initials in capitals. Where more than three authors are concerned in an article, only the first should be named, with *et al.* as reference to the others. (2) Quarterly Cumulative Index Medicus abbreviation of journal name. (3) Volume number. (4) Page number. (5) Year.

References to books should be set out as follows:

PICKWICK, S., *Textbook of Medicine*, Jones and Jones, London, 1st ed., p. 30, 1955.

Illustrations: Photographs should be glossy prints, unmounted and untrimmed, preferably not larger than 10 by 8 inches. Colour work can be published only at the author's expense. Magnification of photomicrographs must always be given. Photographs must not be written on or typed on. Identification can be made by pasting an identifying legend on the back. Patients must not be recognizable in illustrations, unless the written consent of the subject to publication has been obtained. Graphs and diagrams should be drawn in india ink on suitable white paper. Legends to all illustrations should be typed separately from the text of the article. Illustrations should not be rolled or folded.

CLASSIFIED ADVERTISEMENTS

Please send copy to the Advertising Department, Canadian Medical Association Journal, 150 St. George Street, Toronto 5, Ontario.

Rates: \$5.00 for each insertion of 40 words or less, additional words 10c each.

If a box number is required, there will be an additional charge of 50c on the first advertisement to cover postage and handling charges.

Classified advertisements must be at the office of the Journal not later than three weeks prior to date of issue.

Miscellaneous

PROFEX—X RAY UNIT 300 mm A 100 Kv complete with rotating anode tube. Hand-driven, counter-balanced table with fluoroscopic screen and bucky. Diaphragmatic and wall-bucky stand. Used short time. Reasonable. Reply to Box 814, CMA Journal, 150 St. George St., Toronto 5, Ontario.

Office Space

OFFICE with waiting room, examining room and laboratory for sublet from June or July 1960 to April 30, 1961. Located on Sherbrooke St. W., Montreal with convenient parking. Moderate rental. Receptionist service included on request. For further details please write to Box 823, CMA Journal, 150 St. George St., Toronto 5, Ontario.

COMPLETELY EQUIPPED MODERN OFFICE for general practice one block from large shopping center in Hamilton, Ontario. Will rent or sell with or without equipment. Available July 1, 1960. Write Dr. R. Richter, 46 Sherman Ave. S., Hamilton, Ontario.

NEW RESIDENCE AND SUITE for sale or rent. Spacious office, examination room, reception room, washroom, also a large residence. Don Mills district, prominent address, main thoroughfare. Ample parking. Please phone PL 7-3516.

DOCTOR'S SUITE available July 1, 1960. Waiting room, operating room, recovery room. St. Clair and Avenue Road in Toronto. Parking available. \$100 monthly. For further information phone HU. 9-4533.

Positions Wanted

DERMATOLOGIST.—McGill graduate, 1956 American board eligible, desires position with established specialist or group for 1 to 2 years. Available September 1960. Reply Dr. B. Gordon, New York Skin and Cancer Unit, 330 Second Ave., New York 3, N.Y.

GENERAL SURGEON 35, Canadian and American trained, fellowship eligible, would like to associate with another surgeon, clinic or group. Address replies to Box 792, CMA Journal, 150 St. George St., Toronto 5, Ontario.

EUROPEAN 41, 5 years' salaried G.P. in Canada, wishes position as associate or assistant with view to partnership. Available immediately until July 31 for one month locum tenens which could be trial period for permanent association or locum tenens only. Reply to Box 824, CMA Journal, 150 St. George St., Toronto 5, Ontario.

LOCUM AVAILABLE, July or August, married, four children, own car, Saskatchewan licence, for general practice duties. Reply to Box 825, CMA Journal, 150 St. George St., Toronto 5, Ontario.

CANADIAN GRADUATE, 30, married, three years' post-graduate in internal medicine, presently in the United Kingdom, would like position in industry or small group. Adaptable. Some experience in general practice. Available January, 1961. Replies to Box 826, CMA Journal, 150 St. George St., Toronto 5, Ontario.

an all-round defence against



in all its phases

HYPON is a new non codeine analgesic for the relief of transient and chronic pain associated with dysmenorrhoea, rheumatism and neuralgia. Its analgesic properties are provided by N. acetyl paraminophenol, acetylsalicylic acid and phenacetin.

Side effects of depression and constipation associated with long term administration of analgesics are countered by the inclusion of caffeine and a minimal dose of phenolphthalein.

HYPON TABLETS

FORMULA: Each tablet contains:

Acetylsalicylic Acid	200 mg.
N. acetyl paraminophenol	60 mg.
Phenacetin	200 mg.
Caffeine	8 mg.
Phenolphthalein	5 mg.

Dose: One tablet three times daily or as prescribed.
Presented in: Packs of 10, 50 and 300 tablets.

CALMIC LIMITED 220 Bay St., Toronto • Crewe & London, England • Sydney, Australia

Announcing

'ACTIFED'

Decongestant / Antihistamine



THE POTENTIATED DECONGESTANT

provides symptomatic relief of nasal congestion and rhinorrhea of allergic or infectious

origin Many patients whose symptoms are inadequately controlled by decongestants or antihistamines alone respond promptly and favorably to 'ACTIFED'.

	'ACTIFED' contains:	in each	in each tsp.
'Actidil' brand Triprolidine Hydrochloride		Tablet	Syrup
		2.5 mg.	1.25 mg.
'Sudafed' brand Pseudoephedrine Hydrochloride		60 mg.	30 mg.

safe and effective for patients of all ages suffering from upper respiratory tract congestion

DOSAGE

	TABLETS	SYRUP (5 cc. tsp.)	} three times daily
Adults and older children	1	2	
Children 4 months to 6 years of age	½	1	
Infants through 3 months	—	½	



BURROUGHS WELLCOME & CO. (CANADA) LTD., Montreal

NEW

the unique
anorexic agent
free of
CNS
stimulation

*for the . . .
cardiac/hypertensive obese*

New Tenuate provides an anorexic effect which assures appetite inhibition, free of CNS stimulation.¹⁻⁷ ECG studies⁸ prove Tenuate does not affect heart rate, blood pressure, pulse or respiration.

Weight loss with Tenuate averages 1.5 pounds per week.^{3,4} Resultant weight loss, by reducing the cardiac load, improves prognosis . . . and, frequently when hypertensives lose weight, blood pressure drops. Thus Tenuate fulfills an important medical need . . . weight loss in cardiac/hypertensive patients.

PROOF—SAFETY—ECG EVIDENCE⁸

Human I.V. Studies with Tenuate 10 mg., IV equiv. of 100 mg. oral dose (4 times recommended dose)

Patients	Sex	Age	Diagnosis	Blood Pressure		ECG	
				Before Inj.	After Inj.*	Control	After Inj.
E. M.	F	62	Diabetes mellitus. A.S.H.D., compensated. Obesity, postmenopausal.	125/54	116/52	Sinus rhythm. Nonspecific myocardial changes.	No change
F. S.	M	67	A.S.H.D., mild hypertension. Early congestive cardiac failure.	175/90	175/90	Sinus rhythm. Early LVH.	No change
M. A.	F	68	Essential hypertension. Degenerative osteoarthritis. Obesity.	207/104	194/98	Sinus rhythm. Normal tracing.	No change
S. G.	M	30	Normal subject.	126/74	122/78	Sinus rhythm. Normal tracing.	No change
D. A.	M	33	Normal subject.	112/80	121/90	Sinus rhythm. Normal tracing.	No change

*This represents the averages of the readings taken at 30-second and 1-minute intervals for 5 minutes prior to injection and 5 minutes after injection of the drug. The amount of fluctuation was considered insignificant.

as it calms anxiety!

Smooth, balanced action lifts depression as it calms anxiety... rapidly and safely

Balances the mood—no “seesaw” effect of amphetamine-barbiturates and energizers. While amphetamines and energizers may stimulate the patient—they often aggravate anxiety and tension.

And although amphetamine-barbiturate combinations may counteract excessive stimulation—they often deepen depression.

In contrast to such “seesaw” effects, Deprol’s smooth, *balanced* action lifts depression as it calms anxiety—both at the same time.

Acts swiftly—the patient often feels better, sleeps better, within a few days. Unlike the delayed action of most other antidepressant drugs, which may take two to six weeks to bring results, Deprol relieves the patient quickly—often within a few days. Thus, the expense to the patient of long-term drug therapy can be avoided.

Acts safely—no danger of liver damage. Deprol does not produce liver damage, hypotension, psychotic reactions or changes in sexual function—frequently reported with other antidepressant drugs.

Bibliography (13 clinical studies, 858 patients): 1. Alexander, L. (35 patients): Chemotherapy of depression—Use of meprobamate combined with benactyzine (2-diethylaminoethyl benzilate) hydrochloride. J.A.M.A. 166:1019, March 1, 1958. 2. Bateman, J. C. and Carlton, H. N. (50 patients): Meprobamate and benactyzine hydrochloride (Deprol) as adjunctive therapy for patients with advanced cancer. Antibiotic Med. & Clin. Therapy 6:648, Nov. 1959. 3. Beerman, H. M. (44 patients): The treatment of depression with meprobamate and benactyzine hydrochloride. Western Med. 1:10, March 1960. 4. Bell, J. L., Tauber, H., Santy, A. and Pulito, F. (77 patients): Treatment of depressive states in office practice. Dis. Nerv. System 20:263, June 1959. 5. Breitner, C. (31 patients): On mental depressions. Dis. Nerv. System 20:142, (Section Two), May 1959. 6. Gordon, P. E. (50 patients): Deprol in the treatment of depression. Dis. Nerv. System 21:215, April 1960. 7. Landman, M. E. (50 patients): Clinical trial of a new antidepressive agent. J. M. Soc. New Jersey. In press, 1960. 8. McClure, C. W., Papas, P. N., Speare, G. S., Palmer, E., Slattery, J. J., Konefal, S. H., Henken, B. S., Wood, C. A. and Ceresia, G. B. (128 patients): Treatment of depression—New technics and therapy. Am. Pract. & Digest Treat. 10:1525, Sept. 1959. 9. Pennington, V. M. (135 patients): Meprobamate-benactyzine (Deprol) in the treatment of chronic brain syndrome, schizophrenia and senility. J. Am. Geriatrics Soc. 7:656, Aug. 1959. 10. Rickels, K. and Ewing, J. H. (35 patients): Deprol in depressive conditions. Dis. Nerv. System 20:364, (Section One), Aug. 1959. 11. Ruchwarger, A. (87 patients): Use of Deprol (meprobamate combined with benactyzine hydrochloride) in the office treatment of depression. M. Ann. District of Columbia 28:438, Aug. 1959. 12. Settel, E. (52 patients): Treatment of depression in the elderly with a meprobamate-benactyzine hydrochloride combination. Antibiotic Med. & Clin. Therapy 7:28, Jan. 1960. 13. Splitter, S. R. (84 patients): Treatment of the anxious patient in general practice. J. Clin. & Exper. Psychopath. In press, April-June 1960.

Dosage: Usual starting dose is 1 tablet q.i.d. When necessary, this dose may be gradually increased up to 3 tablets q.i.d.

Composition: 1 mg. 2-diethylaminoethyl benzilate hydrochloride (benactyzine HCl) and 400 mg. meprobamate.
Supplied: Bottles of 50 light-pink, scored tablets. Write for literature and samples.

 WALLACE LABORATORIES / Toronto, Ontario


▲ **Deprol** ▲

† TRADE-MARK

an important contribution to treatment of



ACNE



treats their acne while they wash

Fostex Cream and Fostex Cake provide essential actions necessary in treating acne. They are well tolerated and easy for patients to use. Patients simply wash acne skin 2 to 4 times a day with Fostex Cream or Fostex Cake, instead of using soap.

Therapeutic washings with Fostex Cream or Fostex Cake degrease the skin and unblock pores by penetrating and softening blackheads. Drying and peeling actions remove papule coverings, thus permitting drainage of sebaceous glands.



FOSTEX[®] CREAM

FOR OILY ACNE


For therapeutic washing in acne when the skin is very oily and blackheads abound. Fostex Cream provides maximum drying action to degrease the skin and help remove blackheads. It is also used as a therapeutic shampoo in associated dandruff and oily scalp.

FOSTEX CAKE



FOR LESS OILY ACNE

Fostex Cake should be used in relatively less oily acne and for maintenance therapy (when the skin has been made dry and substantially free of blackheads with the initial use of Fostex Cream). Fostex Cake has about half the drying action of Fostex Cream.




degreases the skin helps remove blackheads dries and peels the skin

Available through your drug wholesaler

WESTWOOD PHARMACEUTICALS

Buffalo 13, New York

Canadian Distributor: John A. Huston Company, Ltd., Toronto 10, Canada



Oscar Owlet's
happy choice
for microbes
that need killin'
is **PGAttric**
tried and true
the **tasty**
penicillin

P.G.Atric . . . the convenient, pleasant way to prescribe penicillin

P.G.Atric is a delicious butter-mint candy flavoured paediatric preparation of *soluble oral* Penicillin G-Ammonium in an aqueous vehicle. Each 5 ml. teaspoonful contains 222,125 i.u. PGA, equivalent to 0.125 gm. free penicillin G.

Available in 60 ml. bottles.

BRITISH DRUG HOUSES